AstraZeneca

News

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

News

AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.

News

AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.

News

EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.